Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amylyx Pharmaceuticals

4.64
+0.41009.69%
Volume:341.26K
Turnover:1.57M
Market Cap:411.12M
PE:-1.05
High:4.78
Open:4.35
Low:4.28
Close:4.23
Loading ...

Company Profile

Company Name:
Amylyx Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
123
Office Location:
43 Thorndike Street,Cambridge,Massachusetts,United States
Zip Code:
02141
Fax:
- -
Introduction:
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
Joshua Cohen
Co-Chief Executive Officer and Director
Justin Klee
Co-Chief Executive Officer and Director
George Mclean Milne Jr.
Chair
Daphne Quimi
Director
Isaac Cheng
Director
Paul Fonteyne
Director

Shareholders

Name
Position
Joshua Cohen
Co-Chief Executive Officer and Director
Justin Klee
Co-Chief Executive Officer and Director
James Frates
Chief Financial Officer
Margaret Olinger
Chief Commercial Officer
Patrick D. Yeramian
Chief Medical Officer